All In Biotech

Drug Trial Radar · NCT04849741

A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)

A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

54

Actual

Start

Jun 1, 2021

Primary completion

Aug 22, 2025

Study completion Jul 2034

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Apr 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.

Conditions

  • Alexander Disease

Interventions

  • zilganersenDrug

    zilganersen will be administered by ITB injection.

  • PlaceboDrug

    zilganersen-matching placebo will be administered by ITB injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in the 10-Meter Walk Test (10MWT)Time frame: Baseline and Week 61

Locations

13 sites in 8 countries. Site status is shown where the registry gives one.

  • Lucile Packard Children's Hospital Stanford

    Palo Alto, California

  • Children's Hospital of Atlanta

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Ospedale dei Bambini Vittore Buzzi

    Milan, Italy

  • Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • National Center of Neurology and Psychiatry

    Tokyo, Kodaira-shi, Japan

  • Amsterdam Universitair Medische Centra - Academisch Medisch Centrum

    Amsterdam, North Holland, Netherlands

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.